Tscan Historical Income Statement

TCRX Stock

USD 1.45 0.15 9.38%

Historical analysis of Tscan Therapeutics income statement accounts such as Selling General Administrative of 18.8 M, Total Revenue of 2.7 M, Gross Profit of 3 M or Other Operating Expenses of 79.3 M can show how well Tscan Therapeutics performed in making a profits. Evaluating Tscan Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tscan Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Tscan Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tscan Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

About Tscan Income Statement Analysis

Tscan Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tscan Therapeutics shareholders. The income statement also shows Tscan investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Tscan Therapeutics Income Statement Chart

At this time, Tscan Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 12.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 3.6 M in 2025.

Selling General Administrative Other Operating Expenses Research Development Cost Of Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tscan Therapeutics. It is also known as Tscan Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Tscan Therapeutics income statement and represents the costs associated with goods and services Tscan Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Tscan Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tscan Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.At this time, Tscan Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 12.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 3.6 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Income	1.6M	6.3M	12.1M	12.7M
Net Interest Income	415K	2.4M	8.4M	8.8M

Interest Income Net Interest Income

Tscan Therapeutics income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other	Selling And Marketing Expenses
Net Interest Income		0.98	0.51	0.7	0.0	0.71	-0.88	-0.87	-0.87	0.71	-0.88	0.91	0.71	0.51	-0.87	0.98	-0.87	0.84	-0.93	-0.93
Interest Income	0.98		0.63	0.79	-0.16	0.8	-0.94	-0.93	-0.93	0.81	-0.94	0.96	0.8	0.64	-0.93	1.0	-0.93	0.9	-0.89	-0.89
Depreciation And Amortization	0.51	0.63		0.94	-0.35	0.93	-0.85	-0.86	-0.86	0.92	-0.85	0.7	0.93	1.0	-0.86	0.6	-0.86	0.76	-0.4	-0.4
Selling General Administrative	0.7	0.79	0.94		-0.34	1.0	-0.94	-0.94	-0.94	1.0	-0.93	0.84	1.0	0.94	-0.94	0.77	-0.94	0.86	-0.52	-0.52
Gross Profit	0.0	-0.16	-0.35	-0.34		-0.34	0.21	0.2	0.2	-0.35	0.19	-0.4	-0.34	-0.37	0.21	-0.2	0.21	-0.33	-0.15	-0.15
Other Operating Expenses	0.71	0.8	0.93	1.0	-0.34		-0.94	-0.94	-0.94	1.0	-0.94	0.85	1.0	0.93	-0.94	0.78	-0.95	0.87	-0.53	-0.53
Operating Income	-0.88	-0.94	-0.85	-0.94	0.21	-0.94		1.0	1.0	-0.94	1.0	-0.94	-0.94	-0.85	1.0	-0.92	1.0	-0.94	0.78	0.78
Net Income From Continuing Ops	-0.87	-0.93	-0.86	-0.94	0.2	-0.94	1.0		1.0	-0.94	1.0	-0.93	-0.94	-0.86	1.0	-0.91	1.0	-0.93	0.77	0.77
Ebit	-0.87	-0.93	-0.86	-0.94	0.2	-0.94	1.0	1.0		-0.94	1.0	-0.93	-0.94	-0.86	1.0	-0.91	1.0	-0.93	0.77	0.77
Research Development	0.71	0.81	0.92	1.0	-0.35	1.0	-0.94	-0.94	-0.94		-0.94	0.85	1.0	0.92	-0.95	0.78	-0.95	0.88	-0.53	-0.53
Ebitda	-0.88	-0.94	-0.85	-0.93	0.19	-0.94	1.0	1.0	1.0	-0.94		-0.93	-0.94	-0.85	1.0	-0.91	1.0	-0.93	0.79	0.79
Cost Of Revenue	0.91	0.96	0.7	0.84	-0.4	0.85	-0.94	-0.93	-0.93	0.85	-0.93		0.85	0.7	-0.93	0.97	-0.93	0.94	-0.79	-0.79
Total Operating Expenses	0.71	0.8	0.93	1.0	-0.34	1.0	-0.94	-0.94	-0.94	1.0	-0.94	0.85		0.93	-0.94	0.78	-0.95	0.87	-0.53	-0.53
Reconciled Depreciation	0.51	0.64	1.0	0.94	-0.37	0.93	-0.85	-0.86	-0.86	0.92	-0.85	0.7	0.93		-0.86	0.6	-0.86	0.76	-0.4	-0.4
Income Before Tax	-0.87	-0.93	-0.86	-0.94	0.21	-0.94	1.0	1.0	1.0	-0.95	1.0	-0.93	-0.94	-0.86		-0.91	1.0	-0.93	0.77	0.77
Total Other Income Expense Net	0.98	1.0	0.6	0.77	-0.2	0.78	-0.92	-0.91	-0.91	0.78	-0.91	0.97	0.78	0.6	-0.91		-0.91	0.9	-0.88	-0.88
Net Income	-0.87	-0.93	-0.86	-0.94	0.21	-0.95	1.0	1.0	1.0	-0.95	1.0	-0.93	-0.95	-0.86	1.0	-0.91		-0.93	0.77	0.77
Income Tax Expense	0.84	0.9	0.76	0.86	-0.33	0.87	-0.94	-0.93	-0.93	0.88	-0.93	0.94	0.87	0.76	-0.93	0.9	-0.93		-0.74	-0.74
Non Operating Income Net Other	-0.93	-0.89	-0.4	-0.52	-0.15	-0.53	0.78	0.77	0.77	-0.53	0.79	-0.79	-0.53	-0.4	0.77	-0.88	0.77	-0.74		1.0
Selling And Marketing Expenses	-0.93	-0.89	-0.4	-0.52	-0.15	-0.53	0.78	0.77	0.77	-0.53	0.79	-0.79	-0.53	-0.4	0.77	-0.88	0.77	-0.74	1.0

Click cells to compare fundamentals

Tscan Therapeutics Account Relationship Matchups

Tscan Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Net Interest Income	106K	16K	415K	2.4M	8.4M	8.8M
Interest Income	106K	17K	1.6M	6.3M	12.1M	12.7M
Depreciation And Amortization	1.2M	3.3M	5.1M	5.4M	4.1M	3.6M
Selling General Administrative	6.7M	13.8M	20.4M	26.4M	30.3M	18.8M
Total Revenue	1.1M	10.1M	13.5M	21.0M	2.8M	2.7M
Gross Profit	(19.5M)	6.8M	8.4M	(67.1M)	2.8M	3.0M
Other Operating Expenses	27.3M	58.8M	80.2M	114.5M	137.6M	79.3M
Operating Income	(26.2M)	(48.6M)	(66.6M)	(93.5M)	(134.8M)	(128.1M)
Net Income From Continuing Ops	(26.1M)	(48.6M)	(66.2M)	(88.3M)	(127.5M)	(121.1M)
Ebit	(26.2M)	(48.6M)	(65.0M)	(85.5M)	(123.8M)	(117.7M)
Research Development	20.6M	45.0M	59.8M	88.2M	107.4M	60.6M
Ebitda	(25.0M)	(45.3M)	(59.9M)	(80.1M)	(119.7M)	(113.8M)
Cost Of Revenue	20.6M	3.3M	5.1M	88.2M	101.4M	106.4M
Total Operating Expenses	27.3M	58.8M	80.2M	114.5M	137.6M	79.3M
Reconciled Depreciation	1.2M	3.3M	5.1M	5.6M	4.1M	3.6M
Income Before Tax	(26.1M)	(48.6M)	(66.2M)	(89.2M)	(127.5M)	(121.1M)
Total Other Income Expense Net	106K	16K	415K	4.2M	7.3M	7.7M
Net Income	(26.0M)	(48.6M)	(65.8M)	(89.2M)	(127.5M)	(121.1M)
Income Tax Expense	(106K)	3.1M	(415K)	5.2M	6.0M	6.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tscan Historical Income Statement

About Tscan Income Statement Analysis

Tscan Therapeutics Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Tscan Therapeutics income statement Correlations

Tscan Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tscan Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Tscan Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Other Income Expense Net	+ 1.0	Interest Income
Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Other Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses

Net Income	- 0.95	Total Operating Expenses
Net Income	- 0.95	Research Development
Income Before Tax	- 0.95	Research Development
Net Income	- 0.95	Other Operating Expenses
Income Before Tax	- 0.94	Total Operating Expenses
Total Operating Expenses	- 0.94	Ebitda